Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain
Forty-eight patients with noncancer neuropathic pain who had participated in a randomized controlled trial with intravenous fentanyl (FENiv) infusions received prolonged transdermal fentanyl (FENtd) in an open prospective study. Pain relief, side effects, tolerance, psychological dependence, mood ch...
Gespeichert in:
| Veröffentlicht in: | Journal of pain and symptom management 1998-10, Vol.16 (4), p.220-229 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 229 |
|---|---|
| container_issue | 4 |
| container_start_page | 220 |
| container_title | Journal of pain and symptom management |
| container_volume | 16 |
| creator | Dellemijn, Paul L.I. van Duijn, Hans Vanneste, Jan A.L. |
| description | Forty-eight patients with noncancer neuropathic pain who had participated in a randomized controlled trial with intravenous fentanyl (FENiv) infusions received prolonged transdermal fentanyl (FENtd) in an open prospective study. Pain relief, side effects, tolerance, psychological dependence, mood changes, and quality of life were evaluated. The value of clinical baseline characteristics and the response to FENiv also was evaluated in terms of the outcome with long-term FENtd. Eighteen patients stopped prematurely because of insufficient pain relief, side effects, or both. Among the remaining 30 patients completing the 12-week dose titration protocol, pain relief was substantial in 13 and moderate in five. Quality of life improved (23%,
P < 0.01). Psychological dependence or the induction of depression was not observed. In only one patient did tolerance emerge. There was a significant positive correlation between the pain relief obtained with FENiv and that with prolonged FENtd (
r = 0.59,
P < 0.0001). We conclude that (1) long-term transdermal fentanyl may be effective in noncancer neuropathic pain without clinically significant management problems and (2) A FENiv-test may assist in selecting neuropathic pain patients who might benefit from prolonged treatment with FENtd. |
| doi_str_mv | 10.1016/S0885-3924(98)00070-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70026889</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0885392498000700</els_id><sourcerecordid>70026889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-a090d4235de8a8f3ca0ea3407a5b501718f22d862ae981686c665e7b294668b43</originalsourceid><addsrcrecordid>eNqFkEtLxDAQgIMouj5-gtCDiB6qk6ZJk5OI-AJRQT2H2XSqkT7WpKv4743uokdPw8x88-BjbJfDEQeujh9Aa5kLU5QHRh8CQAU5rLAJ15XIleRilU1-kQ22GeNrgqRQYp2tGw0CSjNhp_dhaIf-mersMRCOHfVj9uHHl5RiH2sKHbbZRapi_9lmvs9uaR6GGY4v3mX36PttttZgG2lnGbfY08X549lVfnN3eX12epO7UsGYIxioy0LImjTqRjgEQlFChXIqgVdcN0VRa1UgGc2VVk4pSdW0MKVSelqKLba_2DsLw9uc4mg7Hx21LfY0zKOtAAqltUmgXIAuDDEGauws-A7Dp-Vgv9XZH3X224s12v6os5DmdpcH5tOO6t-ppavU31v2MTpsm-TH-fi3XOpSVSphJwuMkox3T8FG56l3VPtAbrT14P955AuqeIl2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70026889</pqid></control><display><type>article</type><title>Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB Electronic Journals Library</source><creator>Dellemijn, Paul L.I. ; van Duijn, Hans ; Vanneste, Jan A.L.</creator><creatorcontrib>Dellemijn, Paul L.I. ; van Duijn, Hans ; Vanneste, Jan A.L.</creatorcontrib><description>Forty-eight patients with noncancer neuropathic pain who had participated in a randomized controlled trial with intravenous fentanyl (FENiv) infusions received prolonged transdermal fentanyl (FENtd) in an open prospective study. Pain relief, side effects, tolerance, psychological dependence, mood changes, and quality of life were evaluated. The value of clinical baseline characteristics and the response to FENiv also was evaluated in terms of the outcome with long-term FENtd. Eighteen patients stopped prematurely because of insufficient pain relief, side effects, or both. Among the remaining 30 patients completing the 12-week dose titration protocol, pain relief was substantial in 13 and moderate in five. Quality of life improved (23%,
P < 0.01). Psychological dependence or the induction of depression was not observed. In only one patient did tolerance emerge. There was a significant positive correlation between the pain relief obtained with FENiv and that with prolonged FENtd (
r = 0.59,
P < 0.0001). We conclude that (1) long-term transdermal fentanyl may be effective in noncancer neuropathic pain without clinically significant management problems and (2) A FENiv-test may assist in selecting neuropathic pain patients who might benefit from prolonged treatment with FENtd.</description><identifier>ISSN: 0885-3924</identifier><identifier>EISSN: 1873-6513</identifier><identifier>DOI: 10.1016/S0885-3924(98)00070-0</identifier><identifier>PMID: 9803049</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Administration, Cutaneous ; Adult ; Aged ; Analgesics ; Analgesics, Opioid - therapeutic use ; Biological and medical sciences ; clinical trial ; cutaneous ; Double-Blind Method ; drug treatment ; Female ; fentanyl ; Fentanyl - therapeutic use ; Humans ; Male ; Medical sciences ; Middle Aged ; Neuralgia - drug therapy ; neuropathic pain ; Neuropharmacology ; opioids ; Pain ; Pharmacology. Drug treatments ; quality of life ; side effects ; Time Factors ; transdermal delivery</subject><ispartof>Journal of pain and symptom management, 1998-10, Vol.16 (4), p.220-229</ispartof><rights>1998 U.S. Cancer Pain Relief Committee</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-a090d4235de8a8f3ca0ea3407a5b501718f22d862ae981686c665e7b294668b43</citedby><cites>FETCH-LOGICAL-c460t-a090d4235de8a8f3ca0ea3407a5b501718f22d862ae981686c665e7b294668b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0885392498000700$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1584676$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9803049$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dellemijn, Paul L.I.</creatorcontrib><creatorcontrib>van Duijn, Hans</creatorcontrib><creatorcontrib>Vanneste, Jan A.L.</creatorcontrib><title>Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain</title><title>Journal of pain and symptom management</title><addtitle>J Pain Symptom Manage</addtitle><description>Forty-eight patients with noncancer neuropathic pain who had participated in a randomized controlled trial with intravenous fentanyl (FENiv) infusions received prolonged transdermal fentanyl (FENtd) in an open prospective study. Pain relief, side effects, tolerance, psychological dependence, mood changes, and quality of life were evaluated. The value of clinical baseline characteristics and the response to FENiv also was evaluated in terms of the outcome with long-term FENtd. Eighteen patients stopped prematurely because of insufficient pain relief, side effects, or both. Among the remaining 30 patients completing the 12-week dose titration protocol, pain relief was substantial in 13 and moderate in five. Quality of life improved (23%,
P < 0.01). Psychological dependence or the induction of depression was not observed. In only one patient did tolerance emerge. There was a significant positive correlation between the pain relief obtained with FENiv and that with prolonged FENtd (
r = 0.59,
P < 0.0001). We conclude that (1) long-term transdermal fentanyl may be effective in noncancer neuropathic pain without clinically significant management problems and (2) A FENiv-test may assist in selecting neuropathic pain patients who might benefit from prolonged treatment with FENtd.</description><subject>Administration, Cutaneous</subject><subject>Adult</subject><subject>Aged</subject><subject>Analgesics</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>clinical trial</subject><subject>cutaneous</subject><subject>Double-Blind Method</subject><subject>drug treatment</subject><subject>Female</subject><subject>fentanyl</subject><subject>Fentanyl - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuralgia - drug therapy</subject><subject>neuropathic pain</subject><subject>Neuropharmacology</subject><subject>opioids</subject><subject>Pain</subject><subject>Pharmacology. Drug treatments</subject><subject>quality of life</subject><subject>side effects</subject><subject>Time Factors</subject><subject>transdermal delivery</subject><issn>0885-3924</issn><issn>1873-6513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLxDAQgIMouj5-gtCDiB6qk6ZJk5OI-AJRQT2H2XSqkT7WpKv4743uokdPw8x88-BjbJfDEQeujh9Aa5kLU5QHRh8CQAU5rLAJ15XIleRilU1-kQ22GeNrgqRQYp2tGw0CSjNhp_dhaIf-mersMRCOHfVj9uHHl5RiH2sKHbbZRapi_9lmvs9uaR6GGY4v3mX36PttttZgG2lnGbfY08X549lVfnN3eX12epO7UsGYIxioy0LImjTqRjgEQlFChXIqgVdcN0VRa1UgGc2VVk4pSdW0MKVSelqKLba_2DsLw9uc4mg7Hx21LfY0zKOtAAqltUmgXIAuDDEGauws-A7Dp-Vgv9XZH3X224s12v6os5DmdpcH5tOO6t-ppavU31v2MTpsm-TH-fi3XOpSVSphJwuMkox3T8FG56l3VPtAbrT14P955AuqeIl2</recordid><startdate>19981001</startdate><enddate>19981001</enddate><creator>Dellemijn, Paul L.I.</creator><creator>van Duijn, Hans</creator><creator>Vanneste, Jan A.L.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19981001</creationdate><title>Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain</title><author>Dellemijn, Paul L.I. ; van Duijn, Hans ; Vanneste, Jan A.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-a090d4235de8a8f3ca0ea3407a5b501718f22d862ae981686c665e7b294668b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Administration, Cutaneous</topic><topic>Adult</topic><topic>Aged</topic><topic>Analgesics</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>clinical trial</topic><topic>cutaneous</topic><topic>Double-Blind Method</topic><topic>drug treatment</topic><topic>Female</topic><topic>fentanyl</topic><topic>Fentanyl - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuralgia - drug therapy</topic><topic>neuropathic pain</topic><topic>Neuropharmacology</topic><topic>opioids</topic><topic>Pain</topic><topic>Pharmacology. Drug treatments</topic><topic>quality of life</topic><topic>side effects</topic><topic>Time Factors</topic><topic>transdermal delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dellemijn, Paul L.I.</creatorcontrib><creatorcontrib>van Duijn, Hans</creatorcontrib><creatorcontrib>Vanneste, Jan A.L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pain and symptom management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dellemijn, Paul L.I.</au><au>van Duijn, Hans</au><au>Vanneste, Jan A.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain</atitle><jtitle>Journal of pain and symptom management</jtitle><addtitle>J Pain Symptom Manage</addtitle><date>1998-10-01</date><risdate>1998</risdate><volume>16</volume><issue>4</issue><spage>220</spage><epage>229</epage><pages>220-229</pages><issn>0885-3924</issn><eissn>1873-6513</eissn><abstract>Forty-eight patients with noncancer neuropathic pain who had participated in a randomized controlled trial with intravenous fentanyl (FENiv) infusions received prolonged transdermal fentanyl (FENtd) in an open prospective study. Pain relief, side effects, tolerance, psychological dependence, mood changes, and quality of life were evaluated. The value of clinical baseline characteristics and the response to FENiv also was evaluated in terms of the outcome with long-term FENtd. Eighteen patients stopped prematurely because of insufficient pain relief, side effects, or both. Among the remaining 30 patients completing the 12-week dose titration protocol, pain relief was substantial in 13 and moderate in five. Quality of life improved (23%,
P < 0.01). Psychological dependence or the induction of depression was not observed. In only one patient did tolerance emerge. There was a significant positive correlation between the pain relief obtained with FENiv and that with prolonged FENtd (
r = 0.59,
P < 0.0001). We conclude that (1) long-term transdermal fentanyl may be effective in noncancer neuropathic pain without clinically significant management problems and (2) A FENiv-test may assist in selecting neuropathic pain patients who might benefit from prolonged treatment with FENtd.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9803049</pmid><doi>10.1016/S0885-3924(98)00070-0</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3924 |
| ispartof | Journal of pain and symptom management, 1998-10, Vol.16 (4), p.220-229 |
| issn | 0885-3924 1873-6513 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70026889 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; EZB Electronic Journals Library |
| subjects | Administration, Cutaneous Adult Aged Analgesics Analgesics, Opioid - therapeutic use Biological and medical sciences clinical trial cutaneous Double-Blind Method drug treatment Female fentanyl Fentanyl - therapeutic use Humans Male Medical sciences Middle Aged Neuralgia - drug therapy neuropathic pain Neuropharmacology opioids Pain Pharmacology. Drug treatments quality of life side effects Time Factors transdermal delivery |
| title | Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A18%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolonged%20Treatment%20with%20Transdermal%20Fentanyl%20in%20Neuropathic%20Pain&rft.jtitle=Journal%20of%20pain%20and%20symptom%20management&rft.au=Dellemijn,%20Paul%20L.I.&rft.date=1998-10-01&rft.volume=16&rft.issue=4&rft.spage=220&rft.epage=229&rft.pages=220-229&rft.issn=0885-3924&rft.eissn=1873-6513&rft_id=info:doi/10.1016/S0885-3924(98)00070-0&rft_dat=%3Cproquest_cross%3E70026889%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70026889&rft_id=info:pmid/9803049&rft_els_id=S0885392498000700&rfr_iscdi=true |